Search results | janssen


Partnering Agreements with Johnson and Johnson / Janssen

This report provides all the information you require to better understand Johnson & Johnson 9 Janssen and its partnering interests and activities over the past seven years.


Johnson & Johnson / Janssen: M&A activity 2005-2013

Johnson & Johnson / Janssen has also announced over 16 M&A deals since 2005, with the lead deals being the acquisition of Synthes, Crucell and Mentor

Johnson & Johnson / Janssen: Partnering activity 2005-2013

Johnson & Johnson, known as Janssen in Europe, announced over 176 partnering / licensing deals since 2005, with over 39 deals in 2012 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in cardiovascular, cancer, infectives, central nervous system, genitourinary and metabolic diseases

Partnering with Johnson & Johnson / Janssen: Partnering for a healthier future

Johnson & Johnson is a top pharma company active in partnering, licensing and M&A in biopharmaceuticals, medical devices and diagnostics

Pharma licensing agreement signed for ASP015K between Janssen Biotech & Astellas

Janssen Biotech and Astellas, both top 50 pharma companies have entered into a pharma licensing agreement for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase inhibitor

Dealmakers weekly review – July 17 2012 – Janssen, Evotec, Genmab, Luminex, Nektar

Dealmaking activity rebounds to a year’s high

Dealmakers weekly review – February 13 2012 – Eli Lilly, Roche, UCB, Janssen, Sistemix, TiGenics, Becton Dickinson, SDIX, Aldagen, Carefusion

The news in the past week has been the lack of deal news. The past week has been very quiet on the dealmaking front, with very little of significance in terms of deals from bigpharma or deals with a high headline value

Dealmakers weekly review – January 16 2012 – Janssen, Boehringer, Genentech, BioReliance, Sanofi

The start of 2012 has seen a significant surge in partnering announcements. In addition, the JP Morgan conference in San Francisco has resulted in a rash of announcements of partnering intentions for 2012

Forma Therapeutics snags second deal in a month, this time with Janssen Biotech

In little more than a few days at the start of January, Forma Therapeutics has announced another significant deal, this time with Janssen Biotech

Janssen Biotech snags second major deal, this time with Pharmacyclics

Janssen Biotech has been busy in recent days, first announcing an $800 million partnership with Molecular Partners, and now signing another deal with Pharmacyclics

Janssen secures options to DARPins in deal worth up to $800 million

Janssen Biotech, a subsidiary of Johnson & Johnson, has secured a long term collaborative R&D deal with Molecular Partners for the development of novel multispecific DARPin products for up to four unmet need immunological disease targets


Sorry, your search returned no results.


Janssen and Ichor Medical enter hep B vaccine delivery alliance

Ichor Medical Systems has entered into a product development collaboration and worldwide license agreement with Janssen Pharmaceuticals

Janssen acquires XO1 for ichorcumab

Janssen Pharmaceuticals has acquired XO1 Limited

Vedanta and Janssen partner for VE202

Vedanta Biosciences announced a license agreement with Janssen Biotech, for Vedanta’s lead microbiome pharmaceutical candidate (VE202)

Janssen and AC Immune partner for ACI-35

AC Immune has entered into a worldwide exclusive license agreement and research collaboration with Janssen Pharmaceuticals

Janssen and Vectura partner for anti-inflammatory therapies for asthma/COPD

Vectura has entered into a global development and licence agreement with Janssen Biotech for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD

Janssen and Isis in RNA-targeted therapeutics pact

Isis Pharmaceuticals has entered into a global collaboration with Janssen Biotech to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract

Janssen and Macrogenics enter MGD011 pact

Janssen Biotech had inked a global collaboration and licensing agreement with MacroGenics

Janssen licenses Tipifarnib to EB Pharma

EB Pharma has executed an agreement with Janssen Pharmaceutica for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound

Janssen Biotech inks global collaboration and licensing agreement with MacroGenics.

Janssen Biotech has inked a global collaboration and licensing agreement with MacroGenics.

Halozyme and Janssen in Enhanze technology pact

Halozyme Therapeutics has entered into a worldwide Collaboration and License Agreement with Janssen Biotech for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme’s ENHANZE technology